Fesoterodine for Overactive Bladder
Fesoterodine is an effective antimuscarinic medication for treating overactive bladder (OAB) in adults, started at 4 mg once daily with the option to increase to 8 mg for optimal symptom control, though it carries a higher burden of adverse effects—particularly dry mouth—and treatment discontinuation compared to some alternatives like tolterodine. 1, 2
Indications
Fesoterodine is indicated for adults with urgency urinary incontinence (UUI), urinary frequency, and urgency associated with overactive bladder 2, 3. The 2024 AUA/SUFU guidelines recommend offering antimuscarinic medications like fesoterodine to patients with OAB when behavioral therapies (bladder training, pelvic floor muscle training) have been unsuccessful 2.
Dosing Algorithm
Starting dose: 4 mg once daily 4, 3, 5
Dose escalation: Increase to 8 mg once daily after 4-8 weeks if symptom control is inadequate 3, 5, 6
- High-quality evidence demonstrates dose-dependent efficacy, with 8 mg showing statistically superior improvements over 4 mg in reducing UUI episodes, urgency episodes, and achieving diary-dry rates 3
- The 8 mg dose provides additional benefit in most bladder diary variables except micturition frequency 6
- Approximately 64% of patients opt for dose escalation by week 8 in flexible-dose studies 5
De-escalation option: Can reduce from 8 mg back to 4 mg if tolerability issues emerge 5
Efficacy Profile
Fesoterodine demonstrates moderate-quality evidence for superiority over tolterodine 4 mg ER, with better continence rates (NNTB 18) and improved UI (NNTB 36) 1. When compared head-to-head:
- Fesoterodine 8 mg vs. tolterodine: Significantly greater reductions in UUI episodes, micturitions, urgency episodes, and higher diary-dry rates 3
- Fesoterodine 4 mg vs. placebo: Effective across all age groups, including elderly patients (≥65 years) and vulnerable elderly 5, 7
- Benefits appear within 2 weeks and are sustained throughout treatment 6
Common Side Effects
Most frequent adverse effects (antimuscarinic class effects) 1:
- Dry mouth: 26.1% with 8 mg, 12.9% with 4 mg (vs. 3.4% placebo) 3
- Constipation: 9% with fesoterodine (vs. 3% placebo) 5
- Headache: More common than with tolterodine 1
- Blurred vision (less common than dry mouth/constipation) 1
Number needed to treat for harm (NNTH): 7 (CI 5-9) for any adverse effect—notably worse than tolterodine (NNTH 12) 1
Treatment Discontinuation Risk
Critical consideration: Fesoterodine has a higher discontinuation rate due to adverse effects compared to several alternatives:
- NNTH for discontinuation: 33 (CI 18-102) vs. placebo 1
- Moderate-quality evidence shows discontinuation rates are higher with fesoterodine than tolterodine (NNTH 58) 1
- Only darifenacin and tolterodine have discontinuation rates similar to placebo 1
Contraindications and Cautions
Use with extreme caution or avoid in 2:
- Narrow-angle glaucoma
- Impaired gastric emptying or gastroparesis
- History of urinary retention
- Patients at risk for retention (diabetes, prior abdominal surgery, narcotic use, scleroderma, hypothyroidism, Parkinson's disease, multiple sclerosis)
Cognitive risk counseling required: The 2024 AUA/SUFU guidelines mandate discussing potential dementia and cognitive impairment risk with all patients prescribed antimuscarinics, as evidence suggests cumulative, dose-dependent association with incident dementia 2. Beta-3 agonists (mirabegron) are typically preferred before antimuscarinics for this reason.
Special Populations
Elderly patients (≥65 years): Fesoterodine is effective and generally well-tolerated, with no change in Mini-Mental State Examination scores in 12-week trials 5. Efficacy is maintained regardless of age, though patients on ≥7 concomitant medications experience more adverse effects 1.
Patients with hypertension: No difference in efficacy or safety profile; fesoterodine provides equivalent benefit 7
Men with persistent LUTS on alpha-blockers: Can be added for persistent OAB symptoms 8
Clinical Decision-Making
When to choose fesoterodine:
- Patient requires dose flexibility for symptom optimization
- Previous antimuscarinic failure at lower doses
- Severe UUI episodes requiring aggressive management
When to avoid fesoterodine:
- Elderly patients with cognitive concerns (prefer beta-3 agonists first) 2
- Patients intolerant of anticholinergic side effects (consider tolterodine or darifenacin with lower discontinuation rates) 1
- Contraindications listed above
Common pitfall: Starting at 8 mg—always initiate at 4 mg to assess tolerability before escalation 3, 5.